A team of researchers at Johns Hopkins has just initiated a clinical trial of Prazosin as potential prophylaxis against acute respiratory distress syndrome (ARDS) among Covid patients. (This hypothesis has some support from a retrospective study on non-Covid patients: https://doi.org/10.1101/2020.04.02.20051565 .) Due to the large number of Covid-related clinical trials going on, however, the recruitment is slow and it will be another few months before there will be enough data from the trial.
In parallel with the clinical trial, the Hopkins team (consisting of Bert Vogelstein, Chetan Bettegowda, Shibin Zhou, Susan Athey, others) is eagerly seeking evidences from Covid patients data in observational databases. Would there be interests and bandwidths in the OHDSI community to investigate this question? The Hopkins team and I had conversations with @SCYou and @Jaehyeong_Cho, but we probably need a bit more help in actually running the study. I know @msuchard is still working hard at getting a study package ready for Rasinhibitors, but I am thinking that it should not be too much more work to get this study running on the Covid patients data.
Prazosin would a much safer alternative to hydroxychloroquine (HCQ) if indeed effective, so investigating this question could be a good complement to the HCQ study from Study-a-thon.